Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
Maral Aminpour, Marco Cannariato, Jordane Preto, et al.
Computation (2022) Vol. 10, Iss. 4, pp. 51-51
Open Access | Times Cited: 16

Showing 16 citing articles:

SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
Céline Boschi, David Scheim, Audrey Bancod, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15480-15480
Open Access | Times Cited: 33
A Deadly Embrace: Hemagglutination Mediated by SARS-CoV-2 Spike Protein at Its 22 N-Glycosylation Sites, Red Blood Cell Surface Sialoglycoproteins, and Antibody
David Scheim
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2558-2558
Open Access | Times Cited: 26
Is the antiparasitic drug ivermectin a suitable candidate for the treatment of epilepsy?
Wolfgang Löscher
Epilepsia (2023) Vol. 64, Iss. 3, pp. 553-566
Open Access | Times Cited: 13
Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19
David Scheim, Paola Vottero, Alessandro D. Santin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 23, pp. 17039-17039
Open Access | Times Cited: 12
SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects
Céline Boschi, David Scheim, Audrey Bancod, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 17
In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease
Yuri Alves de Oliveira Só, Katyanna Sales Bezerra, Ricardo Gargano, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 755-755
Open Access | Times Cited: 2
Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours
Jaqueline C. Stone, Pisirai Ndarukwa, David Scheim, et al.
Biologics (2022) Vol. 2, Iss. 3, pp. 196-210
Open Access | Times Cited: 10
COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State
Juan J Chamie, Jennifer A Hibberd, David Scheim
Cureus (2023)
Open Access | Times Cited: 6
Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses
David Scheim, Peter Parry, David J. Rabbolini, et al.
Viruses (2024) Vol. 16, Iss. 4, pp. 647-647
Open Access | Times Cited: 1
When Characteristics of Clinical Trials Require Per-Protocol as Well as Intention-to-Treat Outcomes to Draw Reliable Conclusions: Three Examples
David Scheim, Colleen Aldous, Barbara Osimani, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 11, pp. 3625-3625
Open Access | Times Cited: 3
Computational Prediction of the Interaction of Ivermectin with Fibrinogen
Paola Vottero, Scott Tavernini, Alessandro D. Santin, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11449-11449
Open Access | Times Cited: 3
Omicron SARS-CoV-2 Spike-1 Protein’s Decreased Binding Affinity to α7nAChr: Implications for Autonomic Dysregulation of the Parasympathetic Nervous System and the Cholinergic Anti-Inflammatory Pathway—An In Silico Analysis
Domiziano Doria, Alessandro D. Santin, Jack A. Tuszyński, et al.
BioMedInformatics (2022) Vol. 2, Iss. 4, pp. 553-564
Open Access | Times Cited: 3
Characterization and Fluctuations of an Ivermectin Binding Site at the Lipid Raft Interface of the N-Terminal Domain (NTD) of the Spike Protein of SARS-CoV-2 Variants
Marine Lefebvre, Henri Chahinian, Bernard La Scola, et al.
Viruses (2024) Vol. 16, Iss. 12, pp. 1836-1836
Open Access
Ivermectin is associated with increase in SPO2 in hypoxemic SARS-Cov-2 patients: pharmacodynamic profile and correlates.
O E Babalola, A.A. Ajayi, Thairu Yunusa, et al.
Research Square (Research Square) (2022)
Closed Access | Times Cited: 2
Computation to Fight SARS-CoV-2 (COVID-19)
Simone Brogi, Vincenzo Calderone
Computation (2023) Vol. 11, Iss. 9, pp. 185-185
Open Access
Surgisphere II: Repeated refusals to disclose the death and hospitalization rates for the TOGETHER trial, ivermectin vs. placebo
David Scheim, Jerome Dancis, Colleen Aldous
(2022)
Open Access
Page 1

Scroll to top